摘要
目的:评价单径和双径测量方法在肺癌近期疗效评价中的一致性。方法:对187例非小细胞肺癌患者的近期疗效进行评估。分别采用RECIST和WHO标准进行疗效评估。测量肿瘤最大直径及其最大垂直径,分别以最大径之和(LDs)及最大垂直径乘积之和(LPDs)计算疗效,按照病灶缩小百分比,疗效分为CR、PR、SD和PD。对两种方法的一致性用等级相关方法进行统计分析。结果:两种方法的一致性较好,反应率相关系数rs=0.622,稳定率相关系数rs=0.864,两种评价标准的结果间存在相关关系(P<0.05)。结论:RECIST标准较WHO标准简单易用,两种方法间具有较好的一致性。
Objective： To evaluate the concordance between the single diameter and the double diameter in response rate of the non-small cell lung cancer. Methods： The tumor response rate of 187 patients with lung cancer was evaluated by RECIST and WHO criteria respectively. The largest diameter and perpendicular diameter of tumor were measured and the curative effect was calculated by the sum of the largest diameters （LDs） and the product of multiplication of the largest perpendicular diameters （LPDs） respectively. According to the percentage of tumor shrinkage, response rate was divied into the CR, PR, SD and PD groups. Results： The concordance between the methods was good, and the coefficient correlation of the response rate rs=0.622, and coefficient correlation of stabilization rate rs= 0.864, which showed that there was a correlativity between the two methods （P〈005）. Conclusion： RESCIT is more simple and easy than WHO criteria, and there is a good concordance between the two appraisement methods.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2006年第5期253-255,共3页
Chinese Journal of Clinical Oncology
基金
国家科技部"十五"重点攻关项目基金资助(编号:2001BA701A15b)
